secwatch.observer — SEC 8-K summary
======================================

Issuer:     QuidelOrtho Corp (QDEL)
CIK:        0001906324
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001906324-25-000150
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

QuidelOrtho reports Q2 2025 adjusted EPS of $0.12 vs loss of ($0.07); reaffirms FY guidance
--------------------------------------------------------------------------------

- Q2 revenue $614M (-3.6% YoY); Labs revenue +4% as reported, but respiratory revenue fell 20% to $47M on lower COVID-19 sales.
- GAAP net loss $255M ($3.77 loss per share) vs $148M loss prior year; includes $179M restructuring charges, notably $150M Savanna platform discontinuation.
- Adjusted EBITDA $107M (17% margin, +330 bps YoY); achieved $100M annualized cost savings from 2024 initiatives.
- Reiterates FY2025 guidance: revenue $2.60-$2.81B, adj. EBITDA $575-$615M, adj. diluted EPS $2.07-$2.57.
- Announced intent to acquire LEX Diagnostics; initiated major manufacturing site consolidation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1906324/000190632425000150/0001906324-25-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1906324/000190632425000150/qdel-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001906324-25-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer